NCT06095505Phase 2Recruiting

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Study sponsor: Puma Biotechnology, Inc. · PBYI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-10-30Estimated
Enrollment · participants120Estimated
Source updated2026-08-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Planned enrollment increased by 40 participants

Before: 80 participants (planned). After: 120 participants (planned).

Primary completion date changed

Before: 30 Apr 2027. After: 30 Oct 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview